There’s a quiet irony hiding in the GLP-1 revolution: the drugs are most effective in people with serious obesity-related health conditions, and men disproportionately have those conditions. Yet women are the ones predominantly using the drugs.
It raises a pointed question: why are men sitting this one out?
The Numbers Don’t Lie
Obesity affects men and women at almost identical rates. According to recent data, approximately 43% of men and 42% of women in the United States meet the clinical threshold for obesity. The health risks are comparable too: heart disease, Type 2 diabetes, sleep apnea, joint problems, and more.
But when it comes to seeking treatment, the picture diverges sharply. A RAND Corporation survey of nearly 9,000 Americans found that women use GLP-1 drugs at substantially higher rates than men across most age groups. Among adults aged 30 to 49, women are more than twice as likely to have used a GLP-1 medication as their male peers. A KFF Health Tracking Poll found that about 51% of women expressed interest in using GLP-1 drugs compared to only 31% of men. When it comes to prescriptions, female patients account for roughly three-quarters of all GLP-1 prescriptions written for weight loss, despite men and women carrying nearly the same obesity burden.
That gap isn’t a coincidence. It’s the product of deeply ingrained patterns in how men relate to their health.
“I’ll Handle It Myself”
Ask researchers who study men’s health why this gap exists and you’ll hear a consistent answer: masculinity norms.
Men, across cultures and age groups, consistently visit doctors less often than women. Studies show that among adults in their prime working years, men consult a primary care physician roughly half as often as women, a difference that isn’t explained simply by women attending appointments for reproductive health. Men are more likely to tolerate symptoms, rationalize discomfort, and delay seeking help until a problem becomes impossible to ignore. As one line of research put it, men often resist visiting doctors for minor problems, reflecting a masculine construct of “hardiness,” the idea that needing help signals weakness.
Weight, specifically, carries an added layer. For many men, struggling with weight is framed as a personal failing, something to be solved through discipline, willpower, and hard work at the gym. Seeking medical help for it, particularly a medication, can feel like an admission of defeat. Research on men’s barriers to weight management programs found that help-seeking is often “seen as a feminine act that compromises masculinity,” and that traditional group-based nutrition and exercise programs are perceived by many men as “inherently feminine.”
There’s also a specific stigma around weight-loss drugs. A Kinsey Institute survey of 2,000 single adults found that 60% of male GLP-1 users reported fear of being judged or shamed for taking one, compared to only 35% of women. The concern isn’t irrational: about a quarter of survey respondents said they would not date someone taking a GLP-1, with many citing the belief that weight loss should be managed through lifestyle, not medication.
For men who already resist asking for help, the added social stigma of using a “diet drug” can be enough to keep them away entirely.
The Health Cost of Waiting
The reluctance to seek care has real consequences. Men who avoid the doctor are less likely to have obesity identified, less likely to be referred to any kind of weight management program, and critically, less likely to be diagnosed with the cardiovascular and metabolic conditions that make GLP-1s most valuable.
That’s where the cost becomes acute. Men are statistically more likely than women to die from heart disease, and they tend to develop cardiovascular disease earlier. Obesity is one of the most significant drivers of that risk. Yet the average man with obesity is less likely than the average woman with obesity to be enrolled in treatment of any kind: behavioral, pharmaceutical, or surgical.
For men already living with heart disease or at high cardiovascular risk, GLP-1s aren’t just a weight-loss option. The landmark SELECT trial, which tracked over 17,500 patients with obesity and pre-existing cardiovascular disease, found that semaglutide reduced the risk of heart attack, stroke, or cardiovascular death by up to 20%. The American College of Cardiology now formally recommends GLP-1 drugs as a tool to reduce cardiovascular disease risk. The cardiovascular benefits were consistent across age, gender, race, and body size, meaning men stand to benefit just as much as women, if they can be reached.
When the Doctor Asks, Men Say Yes
Here’s something surprising buried in the research: men’s reluctance to seek help doesn’t mean they’re impossible to reach. It often just means no one has asked them directly.
A clinical trial examining opportunistic weight-loss referrals in primary care found something striking. When primary care physicians proactively offered weight-loss support, including referrals to programs, to patients with obesity regardless of why they came in, seven in ten men accepted the referral. That’s not a dramatic gap from women. When a trusted doctor frames weight management as a medical issue rather than a personal one, men’s resistance softens considerably.
The implication is important: a significant portion of the gender gap in GLP-1 use isn’t men actively refusing treatment. It’s men not being in the healthcare system often enough to be offered it in the first place. Fix the access problem, and the uptake may follow.
The advice here is simple: you should be visiting a doctor regularly!
Is Change Coming?
There are signs that the cultural conversation around men and weight is shifting, slowly.
GLP-1 drugs are increasingly being discussed not as “diet pills” but as medications for chronic disease management, cardiovascular protection, and metabolic health. That reframing matters for men. A man who might resist Wegovy as a weight-loss drug may be more receptive to semaglutide described as a medication that reduces his risk of heart attack. As GW University health experts have noted, as more men become aware of the broader health benefits of these drugs, beyond the number on the scale, the usage trend may begin to change.
There’s also an age factor. RAND data shows that among adults 65 and older, men actually use GLP-1s at slightly higher rates than women. By that stage, chronic disease has often accumulated to the point where medical intervention is no longer optional. The challenge is reaching men earlier, before obesity-related damage compounds.
The new pill formulations arriving in 2026 may also help. Injectable medications require a prescription visit and ongoing clinical engagement, exactly the kind of healthcare interaction men tend to avoid. A daily pill, potentially ordered through a telehealth platform, lowers the friction considerably. Whether that translates to more men actually starting and staying on treatment remains to be seen.
Before You Ask the Doctor, Ask Yourself
The conversation around GLP-1s and men ultimately leads to a question that deserves an honest answer before anyone books an appointment or fills a prescription: have you actually tried?
This isn’t meant to be harsh. It’s meant to be the kind of direct, no-nonsense question that men generally respect and respond to. Because there’s a real difference between a man who has spent two years genuinely changing his diet, building an exercise routine, experimenting with intermittent fasting, and still can’t move the needle on his weight or health markers, and a man who has mostly thought about doing those things but hasn’t committed to them in any sustained way.
That difference matters, and it’s worth being clear-eyed about which camp you’re in.
What a real effort looks like. Changing eating habits in a meaningful way isn’t cutting out dessert for a week. It means consistently reducing processed foods, added sugars, and excess calories over months, not days. Regular exercise means more than occasional weekend activity; research consistently shows that 150 minutes or more of moderate-intensity movement per week, ideally including some strength training, is the baseline for meaningful metabolic benefit. Intermittent fasting, whether a daily eating window or periodic fasting days, has genuine evidence behind it for some people and is worth a serious try if you haven’t explored it. None of these require a gym membership or a personal trainer. They do require consistency over a long enough period to actually measure results. Check out this article we posted years ago if you’re looking for motivation.
When lifestyle alone isn’t enough. Here’s the honest counterpoint: for some men, doing all of those things still won’t be sufficient. If you have a BMI above 35, or if obesity has already contributed to Type 2 diabetes, high blood pressure, heart disease, or sleep apnea, the medical stakes may have escalated beyond what diet and exercise alone can reliably address. Biology works against significant weight loss in ways that have nothing to do with willpower, and the research is clear that for men with serious obesity-related conditions, lifestyle changes are necessary but often not adequate on their own.
The right questions to sit with are straightforward. Have I made a sustained, consistent effort over at least three to six months? Have I tracked what I’m eating, at least roughly, rather than estimating? Have I talked to a doctor about my weight at all, or have I been avoiding that conversation? Do I have health conditions that have gotten worse because of my weight?
If the answer to the first two questions is no, that’s where to start. Diet, movement, and fasting are free, carry no side effect profile, and build habits that actually last. They are not the “hard way” compared to medication; they are simply the foundation, and they are worth giving a genuine chance before escalating.
If the answer to the last two questions is yes, then the conversation with a doctor about GLP-1s isn’t an easy way out. It’s the appropriate next step for a real medical problem that has outgrown what lifestyle changes alone can fix.
The goal in either case is the same: better health, more years, and a body that lets you do the things you want to do. The path to get there should be honest about where you’re actually starting from.
Also, even if you decide to try the GLP-1 route, you should also be focused on healthy habits to maximize the long-term benefits. We’ll address that more in a future article.
What Would It Take?
Closing the gender gap in GLP-1 use isn’t just about men’s individual decisions. It’s about how the healthcare system, pharmaceutical marketing, and cultural messaging are structured.
Weight loss programs have historically been designed and marketed with women in mind. The language, the imagery, the group dynamics have all, often unintentionally, sent a signal that this space isn’t for men. Some clinicians are beginning to recognize that gender-sensitized approaches, framing treatment around performance, vitality, and disease prevention rather than appearance, may be more effective at engaging men.
For men themselves, the most honest message may be this: the same stoicism that drives men to tough things out is the same trait that keeps them from getting help that could meaningfully extend their lives. Obesity is not a discipline problem. Heart disease is not a personal failing. And asking for medical help, including medication, isn’t weakness. It’s the same pragmatic problem-solving that men apply to everything else.
The drugs are there. The evidence is there. The question is whether men will show up to use them.
This article is intended for general informational purposes and does not constitute medical advice. Talk to your doctor to discuss whether GLP-1 medications may be appropriate for you.
